ArticleBiological research2026
Concurrent high-intensity interval plus resistance training improves vascular health in breast cancer survivors with high chemotherapy exposure.
Article in Biological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of Concurrent Training on Resting and Progressive Exercise Metabolism in Breast Cancer Survivors with Metabolic Syndrome Risk Factors.Nutrients · 2026Article
- A short-term concurrent training program enhances arterial stiffness and flow-mediated dilation in overweight or obese women independent of weight loss.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe aim was to determine the effects of 8 weeks of concurrent training of abbreviated high-intensity interval-training and low–load resistance training (CTHIIT+RT) on functional and structural vascular outcomes of breast cancer survivors with a history of high or low exposure to chemotherapy sessions.
methodsBreast cancer survivor women (n = 21, 58.7 ± 8.7 years) were divided into high– (HVchemo, n = 11) or low–volume chemotherapy groups (LVchemo, n = 10). Pulse wave velocity (PWV) and carotid intima–media maximum (cIMTmax) were the primary outcomes, while flow-mediated dilation (FMD), carotid intima–media average (cIMTav), baseline brachial artery diameter (Dbase), peak diameter (Dpeak), and one-repetition maximum tests for the biceps (1RMbc), shoulder (1RMsp), back (1RMback), and leg extension (1RMLeg) served as secondary outcomes.
resultsPWV decreased in the LVchemo group (∆˗1.64 m⋅s− 1, p < 0.001) but not in the HVchemo group. cIMTmax was reduced only in the HVchemo group (∆˗0.23 mm, p = 0.024). FMD was significantly increased in the HVchemo (∆+5.06%, p = 0.023) but not in the LVchemo group. HVchemo and LVchemo groups increased Dbase (∆+0.38 mm, p = 0.005; and ∆+0.16 mm, p < 0.0001) and Dpeak (∆+0.32 mm, p = 0.008; and ∆+0.12 mm, p < 0.0001). HVchemo and LVchemo groups increase 1RMbc (∆+2.3 kg; and ∆+2.09 kg), 1RMsp (∆+2.15 kg; and ∆+2.36 kg), 1RMback (∆+4.4 kg; and ∆+4.58 kg), and 1RMLeg (∆+6.15 kg; and ∆+5.27 kg), all p < 0.01.
conclusionsEight weeks of CTHIIT+RT in women breast cancer survivors who received higher chemotherapy volume reduces cIMTmax, but increases FMD, Dbase, Dpeak, cardiorespiratory fitness, and muscle strength. Vascular improvements were partially observed in subjects with lower chemotherapy volumes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.